United States: View From The Horizon: Digital Health And Cell, Tissue, And Gene Therapies In Boston

On April 30 our new global series, Life Sciences and Health Care Horizons, kicked off in Boston with two panel discussions that focused on the challenges and opportunities that our lawyers and clients are facing in two emerging markets in the industry: (1) cell, tissue, and gene therapies; and (2) digital health technology. This was the first event in a series that will span three continents over the next six months and focus on issues impacting industry leaders around the world. We are excited to share the following highlights from Boston, and we look forward to future discussions as we forecast and help clients prepare for what’s to come.

Cell, Tissue, and Gene Therapies

Cell, tissue, and gene therapies are an emerging area of focus for many life sciences companies in 2019. Since FDA’s approval of the first gene therapy, Novartis’ Kymriah™, in 2017, several other companies are anticipating approval of their cell, tissue, and gene therapy products and over 1,000 more companies are currently engaged in clinical trials.

Our panelists discussed and analyzed the challenges facing these cell, tissue, and gene therapy products, which start in the investigational stage and run through commercialization stage. Vadim Lubarsky, Executive Director of CMS Policy and Reimbursement at Novartis, described the reimbursement and operational issues that Novartis has faced since taking the first FDA-approved gene therapy to market. According to Mr. Lubarsky, the current regulatory framework was not built to properly account for these “one-time curative products” and Novartis has been one of the pioneering companies in the value based pricing for in the gene therapy market. Hogan Lovells partner Ken Choe echoed this sentiment, highlighting the fact that stakeholders throughout the cell, tissue, and gene therapy market, including manufacturers, health care providers and distributors, are continuing to push for regulatory reform, and part of that reform includes different drug pricing models. “Innovative products with reimbursement issues are the ones that lend themselves to [value-based pricing models],” according to Mr. Lubarksy. From Mr. Choe’s perspective, the biggest issue for value-based pricing models is the Medicaid drug rebate program, which discincentivizes manufacturers from having a low best price.

Hogan Lovells partner Hein van den Bos, who is based in our Amsterdam office, described a similar struggle in the EU regulatory framework for these products. Adding additional hurdles is the fact that pricing for these products must be negotiated on an EU-member state level and, depending on logistics, these products may require additional EU member state licenses.

From the commercial contracting perspective, we heard from Adriana Tibbitts, counsel at Hogan Lovells, who explained that the sheer number of contracts associated with these products creates an operational hurdle associated with launch. Mr. Lubarsky agreed with this sentiment, explaining that Novartis had to put hundreds of contracts in place in connection with the commercial launch of Kymriah™. As we continue to see more products approved, we expect that the contracting process will become more streamlined.

As closing remarks, Hogan Lovells partners Michael Druckman and Hein van den Bos echoed what other panelists had noted, which is that as we look to the future of these products, we see a changing landscape from a regulatory, insurance and commercial perspective.

Bridging the digital divide: Developing innovative digital health therapies that integrate a drug and a device

Digital health promises to bring digital technology into the health care arena, improving health and reducing costs. A key area of digital health innovation is the integration of digital health technology with pharmaceutical products. From enhancing access to medicine through telemedicine, to addressing non-adherence with medication-embedded sensors, to prescription digital therapeutics, digital health technologies are reshaping the medical landscape.

Susan Lee, a partner on Hogan Lovells’ Global Digital Health Team, moderated a panel discussion with industry leaders focusing on the future of digital health development and adoption for therapies combining a prescription drug with a medical device. The panel featured Tracy Palmer Berns (Chief Compliance Officer, AMAG Pharmaceuticals), Bruce Carroll (Vice President, Healthcare Policy and Market Access, Proteus Digital Health), Yuri Maricich (Chief Medical Officer and Head of Clinical Development, Pear Therapeutics), and Hogan Lovells counsel Brooke Bumpers.

Panelists highlighted the legal and regulatory challenges impacting the ability to bring these products to market, including FDA’s evolving understanding of digital health technology and application of the 21st Century Cures Act. Panelists noted that even combining an approved drug product with a well characterized digital technology requires substantial regulatory review, as was the case with Abilify MyCite®, the first FDA-approved “digital pill” intended to track the ingestion of medicine.

Similarly, launching prescription digital therapeutics—software-based disease treatments—requires working with FDA to provide a framework for developing products and keeping pace with the need to provide routine software updates. Regulatory innovation, such as FDA’s Software Pre-Certification Pilot Program, was described as essential to ensure the safety and efficacy of products, while enabling digital therapeutics to adapt and improve software without lengthy review processes.

The panel also addressed payment and reimbursement arrangements for digital health products. With enhanced data collection, payment models based on a variety of patient outcomes are possible, and commercial insurers in particular have been open to developing value-based arrangements. Brooke Bumpers noted that payers recognized the potential benefits and cost-savings, but wanted evidence based on established metrics to demonstrate their value.

In addition to educating payers about the value of digital health technologies, the panel discussed the need to engage with patients and health care providers to drive demand and adoption of emerging therapies. Increasing awareness of digital health options and building trust in the use of technology were seen as key to spurring adoption. Panelists spoke about the importance of a regulatory framework that encourages innovation but provides safeguards against ineffective or harmful products to maintain confidence in digital health technology, generally.

The discussion concluded with panelists sharing their optimism that in the near future payment models will develop that will embrace more widespread use of digital health therapies. One panelist predicted that, with increased adoption, we will stop thinking of the products as “digital health” and will view them simply as health care products and therapeutic options.

Life Sciences and Health Care Horizons – Global Event Series

From spotting trends in digital health innovation to breakthrough cures and navigating fluid regulatory landscapes, the Hogan Lovells’ Life Sciences and Health Care Horizons event series will span three continents and feature cutting-edge analysis, engaging panel discussions, and featured keynote speakers.

Save the date

30 April: Boston

16 May: London

27 June: Paris

30 Oct.: Tokyo

6 Nov.: Shanghai

13 Nov.: Northern California

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions